All In Biotech

Drug Trial Radar · NCT00858364

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy

Last checked: Nov 20, 2026Latest source record: Nov 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,549 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,549

Actual

Start

Jul 17, 2009

Primary completion

Jun 7, 2017

Study completion Jun 7, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL compared to participants treated with placebo.

Conditions

  • Non-Small Cell Lung Cancer
  • Anemia
  • Cancer
  • Lung Cancer

Interventions

  • Darbepoetin alfaDrug

    Administered subcutaneously once every 3 weeks

  • PlaceboDrug

    Administered subcutaneously once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization until death or end of study; maximum time on follow-up was 93.6 months.

Locations

566 sites in 37 countries. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Anchorage, Alaska

  • Research Site

    Tucson, Arizona

  • Research Site

    Fayetteville, Arkansas

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Jonesboro, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Arcadia, California

  • Research Site

    Berkeley, California

  • Research Site

    Burbank, California

  • Research Site

    Downey, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Fresno, California

  • Research Site

    Fresno, California

  • Research Site

    La Verne, California

  • Research Site

    Lancaster, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Merced, California

  • Research Site

    Mission Hills, California

  • Research Site

    Montebello, California

  • Research Site

    Oxnard, California

  • Research Site

    Palm Springs, California

  • Research Site

    Pismo Beach, California

  • Research Site

    Pomona, California

  • Research Site

    Redlands, California

  • Research Site

    Salinas, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Simi Valley, California

  • Research Site

    Soquel, California

  • Research Site

    St. Helena, California

  • Research Site

    Torrance, California

  • Research Site

    Vallejo, California

  • Research Site

    West Covina, California

  • Research Site

    Denver, Colorado

Showing 40 of 566 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.